The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services

Journal of Clinical Psychiatry

Volumn 76, Issue 4, 2015, Pages e512-e518

  Paton, Carol ^a,d   Crawford, Michael J ^b   Bhatti, Sumera F ^a   Patel, Maxine X ^c   Barnes, Thomas R E ^a,b  

^a Prescribing Observatory for Mental Health Royal College of Psychiatrists Centre for Quality Improvement   (Taiwan)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADOLESCENT; ADULT; ANXIETY; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG TOLERABILITY; EMOTIONALLY UNSTABLE PERSONALITY DISORDER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MENTAL INSTABILITY; OFF LABEL DRUG USE; PERSONALITY DISORDER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SLEEP DISORDER; UNITED KINGDOM; AFFECTIVE SYMPTOMS; BORDERLINE PERSONALITY DISORDER; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; MENTAL DISORDERS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NATIONAL HEALTH SERVICE; PERSONALITY DISORDERS; PRACTICE GUIDELINE; PSYCHOLOGY; PSYCHOTHERAPY; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECTIVE SYMPTOMS; BORDERLINE PERSONALITY DISORDER; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; ENGLAND; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; PERSONALITY DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; STATE MEDICINE; YOUNG ADULT;

EID: 84932187674     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09228     Document Type: Article

References (28)

1. National Institute for Clinical Excellence. Borderline Personality Disorder-Treatment and Management. London, England: National Institute for Clinical Excellence; 2008.
2. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
3. American Psychiatric Association. Practice guidelines for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(suppl):1-52.
4. National Health and Medical Research Council. Clinical practice guideline for the management of borderline personality disorder. National Health and Medical Research Council, Canberra, Australia. 2012. http://www.nhmrc.gov. au/-files-nhmrc/publications/attachments/mh25-borderline-personality-guideline.pdf. Accessed January 27, 2015.
5. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry. 2001;158(2):295-302. doi:10.176/api.ajp.158.2.295 PubMed
6. Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry. 2004;65(1):28-36. doi:10.408/JCP.v65n0105 PubMed
7. Baker-Glenn W, Steels M, Evans C. Use of psychotropic medication among psychiatric outpatients with personality disorder. Psychiatric Bull. 2010;34(3):83-86. doi:10.192/pb.bp.108.021758
8. Pascual JC, Martín-Blanco A, Soler J, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol. 2010;25(6):349-355. doi:10.1097/YIC.0b013e3283e23ed PubMed
9. Crawford MJ, Kakad S, Rendel C, et al. Medication prescribed to people with personality disorder: The influence of patient factors and treatment setting. Acta Psychiatr Scand. 2011;124(5):396-402. doi:10.1/j.160-047.201.01728.x PubMed
10. Oldham JM, Bender DS, Skodol AE, et al. Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder. J Psychiatr Pract. 2004;10(3):156-161. doi:10.1097/0131746-204050-03 PubMed
11. Prescribing Observatory for Mental Health. What is POMH-UK? http://www. rcpsych.ac.uk/workinpsychiatry/qualityimprovement/nationalclinicalaudits/ prescribingpomh/prescribingobservatorypomh.aspx. Accessed January 27, 2015.
12. IBM SPSS Statistics for Windows Version 20.0 [computer program]. Armonk, NY: IBM Corp; 2011.
13. Coid J, Yang M, Bebbington P, et al. Borderline personality disorder: health service use and social functioning among a national household population. Psychol Med. 2009;39(10):1721-1731. doi:10.1017/S032917080491 PubMed
14. Coid J, Yang M, Tyrer P, et al. Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatry. 2006;188(5):423-431. doi:10.192/bjp.18.5.423 PubMed
15. Use of licensed medicines for unlicensed applications in psychiatric practice. College Report CR142. London, UK: Royal College of Psychiatrists; January 2007. https://www.rcpsych.ac.uk/files/pdfversion/cr142.pdf. Accessed January 27, 2015.
16. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155(12):1733-1739. doi:10.176/ajp.15.12.173 PubMed
17. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71(1):14-25. doi:10.408/JCP.08r04526gre PubMed
18. Lieb K, Vollm B, Rucker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomized trials. Br J Psychiatry. 2010;196(1):4-12. doi:10.192/bjp.bp.108.062984 PubMed
19. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry. 2006;188(1):13-20. doi:10.192/bjp.18.1.13 PubMed
20. Gorwood P, Rouillon F, Even C, et al. Treatment response in major depression: effects of personality dysfunction and prior depression. Br J Psychiatry. 2010;196(2):139-142. doi:10.192/bjp.bp.109.067058 PubMed
21. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722. doi:10.1056/NEJMoa064135 PubMed
22. Sidor MM, MacQueen GM. An update on antidepressant use in bipolar depression. Curr Psychiatry Rep. 2012;14(6):696-704. doi:10.107/s1920-012-0323-6 PubMed
23. Black DW, Blum N, Pfohl B, et al. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention. J Pers Disord. 2004;18(3):226-239. doi:10.1521/pedi.18.3.26.3545 PubMed
24. Nelson K, Schulz SC. Pharmacologic treatment of borderline personality disorder. Current Psychiatry. 2011;10(8):31-40.
25. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-396. doi:10.17/026981070841 PubMed
26. Ripoll LH, Triebwasser J, Siever LJ. Evidence-based pharmacotherapy for personality disorders. Int J Neuropsychopharmacol. 2011;14(9):1257-1288. doi:10.1017/S14614571071 PubMed
27. Ingenhoven TJ, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebocontrolled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011;31(4):489-496. doi:10.1097/JCP.0b013e318217a69 PubMed
28. Fok MLY, Hayes RD, Chang CK, et al. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res. 2012;73(2):104-107. doi:10.1016/j.jpsychores.2012.05.01 PubMed